Renal Drug Dosing in ICU

Answer: What are the key principles of drug dosing adjustment in renal failure?

Answer:

1. Assess renal function using multiple measures (eGFR, creatinine clearance, cystatin C)
2. Determine if drug is renally eliminated (≥30% unchanged in urine)
3. Assess loading dose (depends on volume of distribution, may increase or decrease)
4. Adjust maintenance dose or dosing interval based on remaining renal function
5. Consider active metabolites (nephrotoxic or renally cleared)
6. Account for dialysis removal and adjust for timing
7. Monitor therapeutic drug levels where available
8. Watch for accumulation toxicity
9. Reassess renal function daily in critically ill patients
10. Consider augmented renal clearance in young, septic, or trauma patients

Clinical Overview

Renal dysfunction is present in 30-50% of ICU patients, with acute kidney injury (AKI) affecting up to 60% of critically ill admissions¹. Impaired renal function significantly alters drug pharmacokinetics, necessitating careful dose adjustments to avoid toxicity while maintaining therapeutic efficacy.

Why Renal Dosing Matters

⚠️ Warning: Critical Consideration: Inappropriate drug dosing in renal failure is associated with:

• 2-3 fold increased risk of adverse drug reactions²
• Prolonged ICU stay (average 3-5 days)³
• Increased mortality (OR 1.4-1.8)⁴
• Higher healthcare costs

Renal Impairment Categories

Assessment of Renal Function in ICU

Serum Creatinine Limitations

Serum creatinine is an imperfect marker in critically ill patients due to:

1. Delayed rise after AKI (24-48 hours lag)⁵
2. Muscle mass variations (elderly, sarcopenia, amputation)⁶
3. Fluid overload (dilutional effect)⁷
4. Augmented renal clearance (young, septic, trauma)⁸
5. Non-renal creatinine production (tissue injury, rhabdomyolysis)⁹

Key Point: Clinical Pearl: In septic patients, creatinine may underestimate GFR due to augmented renal clearance (ARC), affecting up to 65% of young trauma patients¹⁰.

Glomerular Filtration Rate Equations

Cockcroft-Gault (1976)

CrCl (mL/min) = [(140 - age) × weight (kg) × factor] / [Serum Cr (μmol/L)]

Where:

• Factor: 1.23 for males, 1.04 for females
• Serum Cr in μmol/L (divide by 88.4 for mg/dL)

Advantages:

• Simple, widely used
• Incorporates body weight
• Drug dosing studies historically used this method¹¹

Disadvantages:

• Overestimates GFR in elderly (reduced muscle mass)
• Underestimates GFR in obesity
• Doesn't account for ethnicity
• Inaccurate in AKI (non-steady state creatinine)

Evidence: Evidence: Cockcroft-Gault tends to overestimate renal function by 10-20% in elderly patients due to age-related sarcopenia, potentially leading to drug toxicity¹².

MDRD (Modification of Diet in Renal Disease) - 2006

eGFR = 175 × [Serum Cr (μmol/L)/88.4]⁻¹·¹⁵⁴ × [Age]⁻⁰·²⁰³ × [0.742 if female] × [1.212 if Black]

For metric units (μmol/L): eGFR = 32788 × [Serum Cr (μmol/L)]⁻¹·¹⁵⁴ × [Age]⁻⁰·²⁰³ × [0.742 if female] × [1.212 if Black]

Advantages:

• More accurate than Cockcroft-Gault in CKD
• Accounts for ethnicity
• Validated in large populations

Disadvantages:

• Less accurate at GFR greater than 60 mL/min/1.73m²
• Not validated in AKI
• Doesn't incorporate body weight
• Underestimates GFR in elderly with low creatinine

Evidence: Evidence: MDRD equation has better correlation with measured GFR than Cockcroft-Gault in CKD stages 3-5, but underestimates GFR in healthy individuals and those with eGFR greater than 60 mL/min/1.73m²¹³.

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - 2009

For females with Scr ≤62 μmol/L (0.7 mg/dL): eGFR = 144 × (Scr/61.9)⁻⁰·³²⁹ × 0·⁹⁹³^Age × 1.018

For females with Scr greater than 62 μmol/L: eGFR = 144 × (Scr/61.9)⁻¹·²⁰⁹ × 0·⁹⁹³^Age × 1.018

For males with Scr ≤80 μmol/L (0.9 mg/dL): eGFR = 141 × (Scr/79.6)⁻⁰·⁴¹¹ × 0·⁹⁹³^Age

For males with Scr greater than 80 μmol/L: eGFR = 141 × (Scr/79.6)⁻¹·²⁰⁹ × 0·⁹⁹³^Age

Advantages:

• Most accurate at higher GFR (greater than 60 mL/min/1.73m²)
• Less bias in elderly
• Recommended by KDIGO¹⁴

Disadvantages:

• More complex calculation
• Still not validated for AKI
• Limited data in ICU populations

Evidence: Evidence: CKD-EPI is 30-40% more accurate than MDRD at GFR greater than 60 mL/min/1.73m² and has less bias in elderly patients and African Americans¹⁵.

Comparison in Clinical Practice

Key Point: Clinical Recommendation: In ICU patients with AKI or rapidly changing renal function, use creatinine clearance from 24-hour urine collection or consider cystatin C-based estimates for drug dosing decisions¹⁶.

Cystatin C and Combined Equations

Cystatin C is produced at constant rate by nucleated cells, filtered by glomeruli, and reabsorbed/catabolized in proximal tubules.

Advantages over creatinine:

• Less affected by muscle mass, age, gender, diet
• Rises earlier in AKI (12-24 hours)¹⁷
• Better predictor of outcomes in AKI

Combined equations (creatinine + cystatin C):

• Most accurate estimate of GFR
• Recommended when eGFR 45-59 mL/min/1.73m² without other CKD markers¹⁸

Evidence: Evidence: Cystatin C-based eGFR identifies 30% more patients with AKI within 24 hours of admission compared to creatinine-based GFR estimates¹⁹.

Augmented Renal Clearance (ARC)

Definition: Measured creatinine clearance greater than 130 mL/min/1.73m²

Epidemiology: 20-65% of ICU patients, particularly:

• Younger patients (below 50 years)²⁰
• Trauma patients (40-65%)²¹
• Sepsis (15-25%)²²
• Burns (30-40%)²³

Pathophysiology:

• Increased cardiac output
• Systemic and renal vasodilation (inflammatory mediators)
• Capillary leak and fluid resuscitation
• Hyperdynamic circulation

Clinical consequences:

• Subtherapeutic drug levels (antibiotics, antivirals, antifungals)
• Treatment failure, resistance development
• Worsening outcomes

Key Point: ARC Risk Factors: Age below 50, trauma, sepsis, low illness severity scores (APACHE II below 15), absence of comorbidities, high fluid balance²⁴.

Pharmacokinetic Principles in Renal Failure

Loading Dose Considerations

Formula: Loading dose = Target concentration × Volume of distribution (Vd)

Renal failure effects on Vd:

Evidence: Evidence: Digoxin loading dose should be reduced by 25-50% in renal failure due to decreased Vd and increased sensitivity to toxic effects²⁵.

Maintenance Dose Adjustments

Two approaches:

1. Dose reduction: Reduce individual dose, maintain interval

   • Preferred for drugs with concentration-dependent toxicity (aminoglycosides)
   • Maintains peak concentrations (important for bactericidal activity)

2. Interval extension: Maintain dose, prolong interval

   • Preferred for time-dependent antibiotics (beta-lactams, vancomycin)
   • Ensures trough levels don't exceed toxic threshold

General formula for dose adjustment:

Adjusted dose = Standard dose × (CrCl_patient / CrCl_normal)

Adjusted interval = Standard interval × (CrCl_normal / CrCl_patient)

Where CrCl_normal = 100 mL/min

Active Metabolites

Renal failure can lead to accumulation of active or toxic metabolites:

⚠️ Warning: High Alert: Normeperidine accumulation from meperidine in renal failure can cause seizures, myoclonus, and serotonin syndrome. Contraindicated in CrCl below 50 mL/min²⁶.

Dialysis Clearance

Factors affecting drug removal:

1. Molecular weight: below 500 Da easily removed, greater than 1000 Da poorly removed
2. Protein binding: Only unbound fraction dialyzable (albumin-bound poorly removed)
3. Volume of distribution: below 1 L/kg well removed, greater than 2 L/kg poorly removed
4. Water solubility: Water-soluble drugs dialyze better
5. Dialysis modality:
   • High-flux hemodialysis: removes larger molecules
   • CRRT: continuous removal, lower clearance per hour
   • Peritoneal dialysis: slower clearance

Supplemental dosing after dialysis:

Antibiotic Dosing in Renal Failure

Beta-Lactams

Pharmacodynamics: Time-dependent killing (fT>MIC)

• Target: 40-70% of dosing interval above MIC for bacteriostasis
• Severe infection: 100% fT>MIC

Penicillins

Special considerations:

• High-dose beta-lactams in ARC may be required (meropenem 2 g q8h, piperacillin-tazobactam 4.5 g q6h)
• Extended/continuous infusions for MIC creep, regardless of renal function²⁷

Evidence: Evidence: CRRT removes 20-40% of piperacillin, meropenem, and cefepime daily. Dose adjustments: piperacillin-tazobactam 4.5 g q8h, meropenem 1 g q8-12h, cefepime 2 g q12h²⁸.

Cephalosporins

Generation 1:

Generation 2:

Generation 3:

⚠️ Warning: Seizure Risk: Cefepime accumulation in severe renal failure (CrCl below 20 mL/min) can cause non-convulsive status epilepticus. Reduce dose to 500 mg q24h or use alternative²⁹.

Carbapenems

Evidence: Evidence: Meropenem is preferred over imipenem in renal failure due to lower seizure risk. CRRT clearance ~30% of normal; dose 1 g q8h for CVVHDF, 1 g q12h for CVVH³⁰.

Glycopeptides

Vancomycin

Pharmacodynamics:

• Traditional: Trough 15-20 mg/L (AUC/MIC correlation)
• Current: AUC/MIC ≥400 (preferred monitoring parameter)

Dosing in renal impairment:

CRRT dosing:

• CVVH/CVVHD: 15-20 mg/kg q24-48h
• CVVHDF: 15-20 mg/kg q24h
• Monitor AUC (target 400-600 mg·h/L)

Evidence: Evidence: AUC/MIC monitoring is superior to trough-only monitoring for vancomycin dosing, reducing nephrotoxicity by 20-30% while maintaining efficacy³¹.

Aminoglycosides

Pharmacodynamics: Concentration-dependent killing (Cmax/MIC)

• Target: Cmax/MIC ≥8-10
• Extended interval dosing: Single daily dose, monitor trough

Dosing in renal impairment:

CRRT dosing:

• Gentamicin: 4-7 mg/kg loading, then 1-1.7 mg/kg q24-48h
• Monitor trough below 1 mg/L

Key Point: Clinical Pearl: Extended interval aminoglycoside dosing (once daily) reduces nephrotoxicity compared to multiple daily dosing, even in renal impairment³².

Fluoroquinolones

⚠️ Warning: Tendon Rupture: Fluoroquinolones have black box warning for tendon rupture, increased risk in renal failure, elderly, and concomitant corticosteroids³³.

Antifungal Agents

Echinocandins

Renal elimination: Minimal (below 5%) Dose: No adjustment needed for renal impairment

CRRT: No adjustment required

Azoles

Evidence: Evidence: Fluconazole CRRT clearance ~50% of normal. Dose 400-800 mg q24h for CVVH/CVVHD, 400 mg q48h for post-dialysis³⁴.

Amphotericin B

Note: Despite no dose adjustment, amphotericin nephrotoxicity worsens outcomes in renal failure. Use lipid formulations in CrCl below 50 mL/min.

Antivirals

Herpesviridae

⚠️ Warning: Neurotoxicity: Acyclovir can cause neurotoxicity (confusion, hallucinations, seizures) in renal failure. Monitor levels if CrCl below 50 mL/min³⁵.

Influenza

HIV

Cardiovascular Medications

Antiarrhythmics

⚠️ Warning: QT Prolongation: Sotalol is contraindicated in CrCl below 40 mL/min due to risk of torsades de pointes. Use alternative beta-blockers³⁶.

Antihypertensives

ACE Inhibitors/ARBs:

• No dose adjustment for most
• Contraindicated in pregnancy, bilateral renal artery stenosis
• Monitor K+ and creatinine
• AKI risk in volume depletion

Beta-blockers:

• Atenolol: 50% renal elimination - reduce dose
• Metoprolol: below 10% renal - no adjustment
• Propranolol: below 1% renal - no adjustment

Calcium channel blockers:

• Diltiazem: below 5% renal - no adjustment
• Verapamil: below 5% renal - no adjustment
• Amlodipine: below 10% renal - no adjustment

Diuretics

Loop diuretics:

Key Point: Clinical Pearl: In advanced CKD, loop diuretics have "ceiling effect." Higher doses may be needed but response often limited. Add metolazone (thiazide-like) for synergistic effect³⁷.

Thiazide diuretics:

• Ineffective when CrCl below 30 mL/min (except metolazone, indapamide)
• Metolazone: active in CKD, useful combination with loop diuretics

Potassium-sparing diuretics:

• Spironolactone: active metabolites - reduce dose in renal failure
• Eplerenone: significant renal elimination - contraindicated CrCl below 30 mL/min
• Amiloride: renal elimination - adjust dose

Anticoagulants

Heparins:

⚠️ Warning: Bleeding Risk: LMWH accumulation in renal failure increases bleeding risk 2-3 fold. Use unfractionated heparin or fondaparinux dose adjustment when CrCl below 30 mL/min³⁸.

Direct oral anticoagulants (DOACs):

Evidence: Evidence: DOACs are contraindicated in CrCl below 15 mL/min (dabigatran, apixaban, edoxaban) or CrCl below 30 mL/min (rivaroxaban). Dose reductions required for CrCl 15-30 mL/min³⁹.

Analgesics and Sedatives

Opioids

⚠️ Warning: Morphine-6-Glucuronide: Active metabolite accumulates in renal failure causing respiratory depression, sedation, and myoclonus. Use fentanyl or hydromorphone instead⁴⁰.

NSAIDs

All NSAIDs are contraindicated in:

• CrCl below 30 mL/min
• AKI
• Volume depletion
• Heart failure

Mechanism of nephrotoxicity:

• Prostaglandin synthesis inhibition (afferent arteriole vasodilation)
• Acute interstitial nephritis
• Fluid retention
• Hyperkalaemia

Safer alternatives:

• Acetaminophen/paracetamol
• Low-dose opioid
• Regional anesthesia

Sedatives

Evidence: Evidence: Midazolam metabolite accumulation in renal failure prolongs sedation. Use lorazepam (non-renal) or dexmedetomidine in prolonged ICU sedation⁴¹.

Antidiabetic Agents

Insulin

No renal adjustment needed

• Monitor more frequently (q4-6h)
• Reduced insulin clearance may increase hypoglycaemia risk
• Decrease insulin requirements in advanced CKD

Oral Antidiabetics

⚠️ Warning: Metformin Lactic Acidosis: Absolute contraindication in eGFR below 30 mL/min. Use with caution and dose reduce if eGFR 30-45 mL/min. Stop in AKI, dehydration, or iodinated contrast⁴².

Anticonvulsants

Electrolyte and Mineral Disorders

Potassium

Hyperkalaemia management in renal failure:

• Calcium gluconate/chloride (membrane stabilization)
• Insulin + dextrose (10 units regular insulin + 25-50g dextrose)
• Salbutamol nebulization (10-20 mg)
• Sodium bicarbonate (if acidotic)
• Potassium binders:
  • "Calcium polystyrene sulfonate (SPS): Contra in bowel obstruction, GI ulceration"
  • "Sodium zirconium cyclosilicate (SZC): Effective, faster onset"
  • "Patiromer: Effective, slower onset (24-48h)"

Phosphate

Hyperphosphataemia in renal failure:

• Phosphate binders:
  • Calcium-based (calcium carbonate, calcium acetate)
  • Non-calcium based (sevelamer, lanthanum)
  • Iron-based (sucroferric oxyhydroxide)
• Dialysis phosphate removal

Calcium

Hypocalcaemia in renal failure:

• Calcium gluconate/chloride for symptomatic hypocalcaemia
• Vitamin D (calcitriol, alfacalcidol) for hypoparathyroidism
• Calcimimetics (cinacalcet) for secondary hyperparathyroidism

Dialysis-Specific Dosing

Intermittent Hemodialysis (IHD)

High-clearance drugs (supplement after HD):

• Aminoglycosides (20-50% removed)
• Vancomycin (30-50% removed)
• Fluoroquinolones (30-60% removed)
• Beta-lactams (30-50% removed)

Moderate-clearance drugs:

• Acyclovir
• Famotidine
• Metformin

Low-clearance drugs (no supplement):

• Digoxin
• Phenytoin
• Vancomycin (high-flux membranes clear 40-50%)
• Anticoagulants

Key Point: HD Timing: Schedule antibiotic dosing after HD when possible. Pre-dialysis levels may be unreliable for drugs removed by dialysis⁴³.

CRRT (CVVH, CVVHD, CVVHDF)

Clearance principles:

• Daily clearance equivalent to 20-40 mL/min GFR
• Depends on effluent flow rate (typically 20-30 mL/kg/h)
• High-flux filters remove larger molecules than IHD

Antibiotic dosing on CRRT:

Evidence: Evidence: CRRT antibiotic clearance varies widely based on effluent rate, filter type, and residual renal function. Therapeutic drug monitoring is essential for vancomycin, aminoglycosides, and beta-lactams in severe infections⁴⁴.

SLED (Sustained Low-Efficiency Dialysis)

Intermediate between IHD and CRRT:

• Duration: 6-12 hours
• Clearance: Lower than CRRT, higher than IHD
• Dosing: Similar to CRRT or intermediate

General approach: Treat as CRRT for dosing, monitor levels closely

Therapeutic Drug Monitoring (TDM)

Indications for TDM

Essential:

• Vancomycin (AUC/MIC or trough)
• Aminoglycosides (peak and trough)
• Digoxin
• Phenytoin (free levels in hypoalbuminaemia)
• Lithium

Consider:

• Beta-lactams in severe infections (target 4-5× MIC)
• Linezolid in refractory infections
• Antifungals (voriconazole, posaconazole)

Sampling Times

Target Ranges

Special Populations

Elderly Patients

Considerations:

• Reduced muscle mass → creatinine underestimates renal impairment
• Increased drug sensitivity (CNS effects, falls)
• Polypharmacy → drug interactions
• Altered protein binding (hypoalbuminaemia)

Strategies:

• Use cystatin C or low creatinine (0.6-0.8 mg/dL) for Cockcroft-Gault
• Start low, go slow
• Monitor for adverse effects more frequently
• Simplify regimens

Obese Patients

Dosing considerations:

• Actual body weight vs ideal body weight vs adjusted body weight
• Adjusted BW = IBW + 0.4 × (Actual BW - IBW)
• Use adjusted weight for hydrophilic drugs (aminoglycosides, vancomycin)
• Use actual weight for lipophilic drugs (most sedatives, opioids)

Critically Ill with AKI

Challenges:

• Rapidly changing renal function
• Fluid overload affecting volume of distribution
• Hypoalbuminaemia affecting protein binding
• Organ dysfunction affecting metabolism
• Drug interactions

Strategies:

• Daily renal function assessment
• Therapeutic drug monitoring where available
• Consider drug dialyzability
• Reassess dosing with renal function changes
• Use non-renally cleared alternatives when possible

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

Higher prevalence of:

• CKD (3-5× higher than non-Indigenous)⁴⁵
• Diabetes mellitus (2-3× higher)
• Cardiovascular disease
• Remote/rural access challenges

Cultural considerations:

• Involve Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs)
• Family involvement in decision-making
• Respect for traditional healers and bush medicine
• Cultural safety in communication

Medication management:

• Simplify regimens (once daily dosing)
• Use fixed-dose combinations
• Consider storage and transportation (remote communities)
• Medication review before discharge to remote areas

Māori Health (Aotearoa NZ):

Whānau-centred care:

• Family decision-making (whānau hui)
• Access to kaumātua (elders)
• Tikanga Māori (cultural protocols)

Higher CKD prevalence: 2-3× non-Māori Increased cardiovascular comorbidities

Renal Transplant Patients

Considerations:

• Variable graft function
• Drug interactions with immunosuppressants (calcineurin inhibitors, mTOR inhibitors)
• Nephrotoxicity risk (CNIs, aminoglycosides, NSAIDs)
• Increased infection risk

Immunosuppressants:

⚠️ Warning: CNI Nephrotoxicity: Cyclosporine and tacrolimus cause acute and chronic nephrotoxicity. Avoid additional nephrotoxins when possible⁴⁶.

Clinical Case Studies

Case 1: Septic Patient with Augmented Renal Clearance

Clinical Case: Patient: 32-year-old male, trauma, sepsis Weight: 85 kg, Height: 180 cm Current: Mechanical ventilation, vasopressors Creatinine: 68 μmol/L (0.77 mg/dL) Urine output: 150-200 mL/h Diagnosis: Pseudomonas aeruginosa pneumonia

Problem: Vancomycin and meropenem levels subtherapeutic on standard dosing

Assessment:

• Cockcroft-Gault CrCl = [(140-32) × 85 × 1.23] / 68 = 168 mL/min
• Augmented renal clearance (ARC) present

Intervention:

• Meropenem: Increase to 2 g q8h (standard 1 g q8h)
• Vancomycin: Increase to 25 mg/kg q12h (standard 15 mg/kg q12h)
• Therapeutic drug monitoring

Outcome: Improved antibiotic levels, clinical resolution of pneumonia

Learning: ARC is common in young trauma/septic patients. Consider higher antibiotic doses when high CrCl present⁴⁷.

Case 2: Elderly Patient with AKI on CRRT

Clinical Case: Patient: 78-year-old female, septic shock Weight: 55 kg Baseline Creatinine: 78 μmol/L (0.88 mg/dL) Current Creatinine: 245 μmol/L (2.77 mg/dL) CRRT: CVVHDF, effluent 25 mL/kg/h Infection: MRSA bacteremia

Problem: Vancomycin dosing uncertainty

Assessment:

• Cockcroft-Gault (baseline): [(140-78) × 55 × 1.04] / 78 = 45 mL/min
• AKI, CRRT replaces renal function
• CRRT clearance ~25 mL/min equivalent

Intervention:

• Vancomycin: 20 mg/kg q24h (1.1 g)
• AUC/MIC monitoring (target 400-600)
• Adjust based on levels

Outcome: Achieved target AUC, cleared bacteremia

Learning: CRRT provides moderate clearance. Use intermediate dosing between standard renal failure and normal function. TDM essential⁴⁸.

Drug Interaction Considerations

Common Interactions Affecting Renal Clearance

P-glycoprotein Interactions

P-gp is an efflux transporter in renal tubules. Inhibition increases renal drug accumulation:

P-gp inhibitors:

• Amiodarone
• Verapamil
• Quinidine
• Cyclosporine
• Ritonavir

P-gp substrates affected:

• Digoxin (2-3 fold level increase)
• Dabigatran
• Tacrolimus

Key Point: Clinical Pearl: When adding a P-gp inhibitor, anticipate increased levels of P-gp substrates and adjust doses accordingly, particularly for digoxin and dabigatran⁴⁹.

Pediatric Considerations

Renal Function Assessment

Schwartz formula (children below 16 years):

eGFR (mL/min/1.73m²) = [0.413 × Height (cm)] / Serum Cr (μmol/L)

For infants (below 1 year): eGFR = [0.45 × Height (cm)] / Serum Cr (μmol/L)

Pediatric Dosing Principles

Dose calculation:

• Use body weight or body surface area
• Adjust for renal function
• Therapeutic drug monitoring essential

Common pediatric renal adjustments:

Red Flags and Warnings

⚠️ Warning: Immediate Action Required:

1. Vancomycin trough greater than 20 mg/L → Increased nephrotoxicity risk. Reduce dose, monitor renal function
2. Aminoglycoside trough greater than 2 mg/L → Increased nephrotoxicity risk. Reduce dose, consider alternative
3. Digoxin level greater than 2 ng/mL → Toxicity risk. Hold doses, consider digoxin Fab fragments
4. Lithium level greater than 1.5 mmol/L → Toxicity risk. Hold doses, enhance elimination
5. Morphine accumulation (sedation, respiratory depression) → Switch to fentanyl or hydromorphone
6. Metformin in AKI → Stop immediately, monitor for lactic acidosis
7. ACEI/ARB in AKI → Hold if creatinine rise greater than 30% or hyperkalaemia
8. NSAIDs in renal failure → Stop immediately, consider alternatives
9. Contrast in renal failure → Use low-osmolar contrast, hydration, consider N-acetylcysteine
10. Sotalol in CrCl below 40 → Switch alternative beta-blocker

Assessment Questions

SAQ Practice Questions

SAQ 1: Antibiotic Dosing in Renal Failure

Question: A 68-year-old male (85 kg) is admitted to ICU with septic shock from presumed intra-abdominal source. His blood cultures grow Klebsiella pneumoniae resistant to ceftriaxone but susceptible to meropenem and piperacillin-tazobactam. He has oliguria (below 0.5 mL/kg/h for 12 hours) with rising creatinine from 88 μmol/L (1.0 mg/dL) on admission to 280 μmol/L (3.2 mg/dL) currently. His blood pressure is 85/50 mmHg on norepinephrine 0.2 μg/kg/min.

a. Calculate his creatinine clearance using Cockcroft-Gault equation. (3 marks)

b. Outline your antibiotic dosing strategy for meropenem in this patient, including justification for your approach. (6 marks)

c. If the patient requires renal replacement therapy, describe how your dosing would change for CRRT (CVVHDF) and intermittent hemodialysis (IHD). (6 marks)

Answer:

(a) Creatinine clearance calculation (3 marks):

Cockcroft-Gault formula:

• CrCl = [(140 - age) × weight (kg) × 1.23] / Serum Cr (μmol/L)
• CrCl = [(140 - 68) × 85 × 1.23] / 280
• CrCl = [72 × 85 × 1.23] / 280
• CrCl = 7521 / 280
• CrCl = 26.9 mL/min

Interpretation: Severe renal impairment (CrCl 15-29 mL/min) (1 mark for calculation, 1 mark for correct formula use, 1 mark for interpretation)

(b) Meropenem dosing strategy (6 marks):

Considerations:

• Severe sepsis requiring adequate antibiotic exposure (1 mark)
• Renal impairment requiring dose adjustment (1 mark)
• Hemodynamic instability (1 mark)
• Meropenem is 70-80% renally eliminated (1 mark)

Dosing:

• Standard dose: 1 g q8h (for normal renal function)
• Severe renal impairment (CrCl 10-29 mL/min): 500 mg q12-24h
• However, for severe sepsis in critically ill, consider extended or continuous infusion to maximize fT>MIC

Recommended approach:

• Meropenem 500 mg q8h OR
• Meropenem 1 g q12h (higher dose given sepsis severity) (2 marks)

Rationale:

• Dose reduction required due to renal impairment to avoid neurotoxicity (seizures)
• Higher end of recommended dosing given severe sepsis and high mortality risk
• Extended infusion (3 hours) may improve target attainment despite dose reduction
• Therapeutic drug monitoring not routinely available but monitor clinical response and renal function
• Reassess dosing daily as renal function may recover or worsen

(c) CRRT and IHD dosing (6 marks):

CRRT (CVVHDF) (3 marks):

• CRRT provides clearance equivalent to approximately 20-40 mL/min GFR
• Meropenem is cleared by CRRT (approximately 30-40% of dose)
• Recommended dosing: 1 g q8-12h for CVVHDF (1 mark)
• If effluent rate high (greater than 30 mL/kg/h): 1 g q8h (1 mark)
• If effluent rate standard (20-25 mL/kg/h): 1 g q12h (1 mark)

IHD (3 marks):

• IHD removes significant meropenem (30-50%)
• Standard dosing for dialysis patients: 500 mg q24h (1 mark)
• Supplemental dosing after dialysis: 500 mg (1 mark)
• Timing: Administer dose after dialysis session (1 mark)

Key points:

• CRRT dosing is higher than non-dialysis renal failure due to continuous clearance
• IHD dosing requires supplemental dose after dialysis session
• Monitor renal function and adjust dosing as recovery occurs

---

SAQ 2: Vancomycin and Augmented Renal Clearance

Question: A 24-year-old female (55 kg) is admitted to ICU after motor vehicle crash with multiple fractures, traumatic brain injury, and ventilator-associated pneumonia (VAP). Sputum culture grows MRSA. Her current medications include fentanyl infusion, propofol, and vancomycin 1 g q12h started 48 hours ago. Her creatinine is 42 μmol/L (0.48 mg/dL), stable since admission. Urine output is 150-200 mL/h. Her first vancomycin trough level (drawn before 4th dose) is 8 mg/L.

a. Calculate her creatinine clearance using Cockcroft-Gault equation and interpret the significance. (3 marks)

b. Explain why her vancomycin level is subtherapeutic and outline your dosing adjustment strategy. (6 marks)

c. Discuss the concept of augmented renal clearance (ARC) and its implications for antibiotic dosing in ICU patients. (6 marks)

Answer:

(a) Creatinine clearance calculation (3 marks):

Cockcroft-Gault formula:

• CrCl = [(140 - age) × weight (kg) × 1.04] / Serum Cr (μmol/L)
• CrCl = [(140 - 24) × 55 × 1.04] / 42
• CrCl = [116 × 55 × 1.04] / 42
• CrCl = 6635.2 / 42
• CrCl = 158 mL/min

Interpretation: Augmented renal clearance (ARC) defined as CrCl greater than 130 mL/min (1 mark for calculation, 1 mark for correct formula, 1 mark for ARC identification)

(b) Vancomycin level interpretation and adjustment (6 marks):

Why level is subtherapeutic:

• Standard vancomycin dosing: 15-20 mg/kg q12h (825-1100 mg q12h for this patient)
• Current dose: 1 g q12h (approx 18 mg/kg) - appropriate weight-based dose
• However, her CrCl of 158 mL/min indicates accelerated clearance (1 mark)
• Vancomycin is 60-80% renally eliminated
• Target trough for severe infection: 15-20 mg/L
• Her level of 8 mg/L is significantly below target (1 mark)

Adjustment strategy:

• Increase vancomycin dose to 20-25 mg/kg q12h (1.1-1.4 g q12h) (2 marks)
• Alternatively, consider q8h dosing: 15-20 mg/kg q8h (1 mark)
• Monitor trough levels after 3-4 doses (before 4th or 5th dose)
• Consider AUC/MIC monitoring if available (more accurate than trough)
• Monitor renal function daily as ARC may normalize

Target:

• Trough 15-20 mg/L (standard monitoring)
• AUC/MIC 400-600 (preferred monitoring if available)
• Watch for nephrotoxicity with higher doses (though less common in ARC)

(c) Augmented renal clearance implications (6 marks):

Definition and epidemiology:

• ARC: Measured CrCl greater than 130 mL/min/1.73m² (1 mark)
• Occurs in 20-65% of ICU patients
• Higher prevalence in:
  • Younger patients (below 50 years)
  • Trauma patients (40-65%)
  • Sepsis (15-25%)
  • Burns (30-40%)

Pathophysiology (2 marks):

• Increased cardiac output (hyperdynamic circulation)
• Systemic and renal vasodilation (inflammatory mediators)
• Capillary leak with aggressive fluid resuscitation
• Enhanced renal perfusion and filtration
• Low creatinine production in young, muscular patients (artificially low serum Cr)

Clinical implications for antibiotics (3 marks):

• Subtherapeutic drug levels with standard dosing
• Treatment failure in infections
• Development of antibiotic resistance
• Worsening clinical outcomes

Antibiotics commonly affected:

• Beta-lactams (penicillins, cephalosporins, carbapenems)
• Vancomycin
• Aminoglycosides
• Linezolid
• Fluoroquinolones
• Acyclovir
• Antifungals (fluconazole)

Management:

• Calculate CrCl daily in at-risk patients
• Use actual body weight for dosing calculations
• Consider higher antibiotic doses or more frequent intervals
• Therapeutic drug monitoring (vancomycin, aminoglycosides, beta-lactams if available)
• Monitor clinical response closely
• Adjust dosing as patient condition evolves (ARC may resolve or persist)

Viva Practice Questions

Viva 1: Renal Drug Dosing Principles

Examiner: Let's discuss drug dosing in renal failure. How do you approach dosing adjustments in a patient with impaired renal function?

Candidate: I approach dosing adjustments in renal failure by considering several key principles. First, I assess the patient's renal function using appropriate measures - serum creatinine, creatinine clearance calculations, and potentially cystatin C in critically ill patients. Then I determine if the drug is significantly renally eliminated, typically if more than 30% is excreted unchanged in urine. For loading doses, I consider the volume of distribution which may be altered in renal failure - for example, decreased in drugs like digoxin due to reduced tissue binding, or increased in conditions with fluid overload.

Examiner: Good. Which equation would you use to estimate renal function in the ICU, and why?

Candidate: In the ICU, I would typically use the Cockcroft-Gault equation for drug dosing purposes, as most drug dosing studies and references are based on this method. However, I'm aware of its limitations in critically ill patients. It tends to overestimate renal function in elderly patients due to sarcopenia, and can be inaccurate in acute kidney injury due to non-steady state creatinine levels. The MDRD equation is more accurate for chronic kidney disease staging but less accurate in patients with higher GFR, and the CKD-EPI equation is most accurate across a wide range of GFR but hasn't been specifically validated for AKI dosing decisions.

Examiner: What are the limitations of serum creatinine as a marker of renal function in ICU patients?

Candidate: Serum creatinine has several important limitations in critically ill patients. There's a significant delay between AKI onset and creatinine rise - typically 24-48 hours - which means creatinine may underestimate the degree of renal impairment early in the course. Creatinine production depends on muscle mass, so elderly patients with sarcopenia or amputees may have low creatinine despite significant renal impairment. Conversely, fluid overload, which is common in ICU patients, can cause dilutional lowering of creatinine. There's also augmented renal clearance in young, septic, or trauma patients where creatinine may underestimate actual GFR. Additionally, non-renal creatinine production can occur with tissue injury or rhabdomyolysis, falsely elevating levels.

Examiner: Excellent. Can you explain the difference between dose reduction versus interval extension for maintenance dosing in renal failure?

Candidate: Yes, there are two main approaches. Dose reduction involves giving a lower amount of drug while maintaining the same dosing interval. This is typically preferred for drugs with concentration-dependent toxicity, such as aminoglycosides, where maintaining peak concentrations is important for efficacy but avoiding high troughs minimizes toxicity. Interval extension involves giving the same dose but prolonging the time between doses. This approach is preferred for time-dependent antibiotics like beta-lactams and vancomycin, where we want to ensure trough levels don't exceed toxic thresholds. The choice between these approaches depends on the drug's pharmacodynamics, therapeutic index, and clinical context.

Examiner: How does renal failure affect the loading dose of drugs?

Candidate: The loading dose depends on the volume of distribution rather than renal function. In renal failure, the volume of distribution can increase, decrease, or stay the same depending on the drug and patient factors. For example, digoxin has a decreased volume of distribution in renal failure, so its loading dose should be reduced by 25-50%. In contrast, aminoglycosides may have a slightly increased volume of distribution in fluid-overloaded patients, so the loading dose might be modestly increased. However, for most antibiotics and many other drugs, the volume of distribution is relatively unchanged, so standard loading doses are appropriate even in renal failure.

Examiner: What is augmented renal clearance and which patients are at risk?

Candidate: Augmented renal clearance is defined as a measured creatinine clearance greater than 130 mL/min/1.73m². It's particularly common in ICU patients with hyperdynamic circulation. Risk factors include younger age - especially under 50 years old, trauma patients where up to 65% may have ARC, sepsis in about 15-25% of patients, burn patients, and those with low illness severity scores. The pathophysiology involves increased cardiac output, systemic and renal vasodilation from inflammatory mediators, capillary leak with fluid resuscitation, and enhanced renal perfusion. The clinical significance is that these patients can have subtherapeutic drug levels on standard dosing, leading to treatment failure, particularly with antibiotics.

Examiner: How would you adjust antibiotic dosing in a patient with ARC?

Candidate: For patients with augmented renal clearance, I would consider using higher antibiotic doses or more frequent dosing intervals. For beta-lactams like piperacillin-tazobactam, I might increase from the standard 4.5 g q8h to 4.5 g q6h, or use extended infusions. For meropenem, I might increase to 2 g q8h rather than the standard 1 g q8h. For vancomycin, I would calculate dosing based on actual body weight and might use 20-25 mg/kg q8h or q12h depending on the CrCl. Therapeutic drug monitoring is essential in these patients to ensure adequate drug exposure while avoiding toxicity. I would also monitor renal function daily as ARC can normalize or persist depending on the clinical course.

Examiner: What about active metabolites in renal failure? Can you give some examples?

Candidate: This is an important consideration because some drugs have active or toxic metabolites that accumulate in renal failure, requiring dose reduction or avoidance. Classic examples include morphine, whose active metabolite morphine-6-glucuronide accumulates causing respiratory depression and prolonged sedation. Meperidine or pethidine has normeperidine which is neurotoxic and can cause seizures, so it's contraindicated in renal failure. Allopurinol produces oxypurinol which accumulates and can cause toxicity and hypersensitivity reactions. Procainamide's metabolite NAPA is active and renally cleared, so procainamide should be avoided. Cefepime has been associated with neurotoxicity including seizures in severe renal failure due to accumulation of unknown metabolites.

Examiner: Excellent. Now, tell me about drug removal by dialysis. What factors affect how well a drug is dialyzed?

Candidate: Several factors determine how well a drug is removed by dialysis. Molecular weight is important - drugs under 500 Daltons are easily removed, while those over 1000 Daltons are poorly removed. Protein binding matters because only the unbound fraction is dialyzable, so highly albumin-bound drugs are poorly removed. The volume of distribution is critical - drugs with a Vd less than 1 L/kg are well removed, while those greater than 2 L/kg are poorly removed because most of the drug is in tissues rather than plasma. Water solubility affects dialyzability, with water-soluble drugs being removed more effectively. Finally, the dialysis modality itself matters - high-flux hemodialysis can remove larger molecules, continuous therapies provide slower but continuous removal, and peritoneal dialysis typically has lower clearance.

Examiner: Can you give me examples of drugs that are significantly removed by dialysis?

Candidate: Yes, drugs that are significantly removed include aminoglycosides like gentamicin and tobramycin, where about 20-50% can be removed in a standard hemodialysis session. Vancomycin is 30-50% removed by hemodialysis, especially with high-flux membranes. Fluoroquinolones like ciprofloxacin and levofloxacin have significant dialysis clearance. Beta-lactams are typically 30-50% removed. Acyclovir is highly dialyzable due to its low protein binding and water solubility. These drugs typically require supplemental dosing after dialysis or dose adjustment for patients on CRRT.

Examiner: What about drugs that are poorly removed by dialysis?

Candidate: Drugs poorly removed by dialysis include digoxin, which has a large volume of distribution and is significantly protein-bound. Phenytoin is also poorly removed due to high protein binding. Lipid-soluble drugs like propofol, benzodiazepines, and many opioids are generally not removed. Anticoagulants like heparin are not removed, and drugs with extensive tissue distribution like vancomycin are incompletely removed by standard dialysis.

Examiner: How do you approach antibiotic dosing on CRRT compared to intermittent hemodialysis?

Candidate: CRRT provides continuous clearance equivalent to approximately 20-40 mL/min of GFR, so antibiotic dosing is typically intermediate between standard renal failure and normal function. The exact dosing depends on the effluent flow rate - higher effluent rates (greater than 30 mL/kg/h) require higher doses. For CVVHDF, I might use meropenem 1 g q8-12h, vancomycin 15-20 mg/kg q24-48h, and piperacillin-tazobactam 4.5 g q8h. For intermittent hemodialysis, the approach is quite different - we give supplemental doses after dialysis sessions because drugs are removed during treatment. For example, vancomycin might be dosed at 15-20 mg/kg and given after dialysis, or a supplemental dose given post-dialysis. Timing of doses relative to dialysis sessions is important - we want to avoid giving drugs immediately before dialysis when they'll be rapidly removed.

Examiner: Very good. What is therapeutic drug monitoring and when is it indicated?

Candidate: Therapeutic drug monitoring involves measuring drug concentrations to optimize dosing, ensuring efficacy while minimizing toxicity. Essential indications include vancomycin, where we monitor either trough levels or the AUC/MIC ratio. Aminoglycosides require both peak and trough monitoring. Digoxin levels are monitored due to its narrow therapeutic index. Phenytoin levels are important, particularly free levels in hypoalbuminemia. Lithium also requires careful monitoring. We should consider TDM for beta-lactams in severe infections or immunocompromised patients to ensure adequate drug exposure, and for antifungals like voriconazole and posaconazole where therapeutic ranges have been established.

Examiner: Thank you. You've covered renal drug dosing comprehensively.

---

Viva 2: Clinical Drug Dosing Scenarios

Examiner: I'd like to discuss some clinical scenarios involving drug dosing in renal impairment. Let's start with an 82-year-old patient with chronic kidney disease admitted to ICU with community-acquired pneumonia. Her baseline creatinine is 180 μmol/L (2.0 mg/dL) and she weighs 50 kg. You need to treat with appropriate antibiotics. What would you prescribe?

Candidate: First, I need to assess her renal function. Using the Cockcroft-Gault equation: CrCl equals [(140 minus age) times weight times 1.04] divided by serum creatinine. For this patient, that's [(140 minus 82) times 50 times 1.04] divided by 180, which equals approximately 17 mL/min. This indicates severe renal impairment with kidney failure.

For CAP in an elderly patient with severe CKD, I need to choose antibiotics that are effective but safe in renal impairment. I would typically consider combination therapy with a beta-lactam plus a macrolide. However, I need to be careful with renally cleared antibiotics. I might use ceftriaxone, which is minimally renally excreted and doesn't require dose adjustment, combined with azithromycin, which is also primarily hepatically cleared. If MRSA is a concern, I could use vancomycin but would need significant dose adjustment - probably 15-20 mg/kg every 3-4 days, with careful monitoring of trough levels.

Examiner: Good choice. Now, what if this patient was in pain and required analgesia? How would you approach pain management in renal failure?

Candidate: Pain management in renal failure requires careful consideration. I would avoid morphine because its active metabolite morphine-6-glucuronide accumulates and can cause respiratory depression and prolonged sedation. Meperidine or pethidine is contraindicated because normeperidine accumulation causes seizures. NSAIDs should be avoided in this degree of renal impairment as they can worsen kidney function and cause fluid retention and hyperkalaemia.

Better options include fentanyl, which is minimally renally cleared and doesn't have active metabolites. The dose wouldn't need adjustment for renal function. Hydromorphone is another option, though it does require some dose reduction in severe renal impairment. Acetaminophen or paracetamol is safe at standard doses. For neuropathic pain, I'd be cautious with gabapentin and pregabalin as they are renally cleared and would require significant dose reduction or may be contraindicated at this GFR level.

Examiner: This patient develops atrial fibrillation with rapid ventricular response. You decide to use amiodarone for rhythm control. What do you need to consider regarding drug interactions with renal medications?

Candidate: Amiodarone is primarily hepatically metabolized and doesn't require dose adjustment for renal failure, which makes it a good choice in this patient. However, amiodarone is a potent inhibitor of P-glycoprotein, which is an important transporter in renal tubules. This is significant because many drugs excreted by the kidneys are P-gp substrates.

Particularly important is the interaction with digoxin. Amiodarone can increase digoxin levels by 2-3 fold, so if the patient were on digoxin, I would need to reduce the digoxin dose by 50% and monitor levels closely. Other relevant interactions include warfarin, where amiodarone increases the INR, requiring warfarin dose reduction. There are also potential interactions with direct oral anticoagulants like dabigatran, which is a P-gp substrate.

I should also consider that amiodarone has many other side effects unrelated to renal function, including thyroid, pulmonary, and hepatic toxicity, which need monitoring.

Examiner: Good. The patient's blood pressure remains elevated at 160/90 mmHg. You want to start antihypertensive therapy. What would you consider?

Candidate: In an 82-year-old with severe CKD, I need to choose antihypertensives carefully. I would avoid ACE inhibitors or ARBs in the acute setting because they can worsen acute kidney injury, especially in volume depletion or with other nephrotoxic insults. If we eventually use them, I'd need to monitor creatinine and potassium closely, stopping if creatinine rises by more than 30% or if hyperkalaemia develops.

Beta-blockers are generally safe, though I need to choose the right one. Metoprolol is primarily hepatically cleared and doesn't need dose adjustment, while atenolol is 50% renally cleared and would require dose reduction. Calcium channel blockers like amlodipine are also safe without dose adjustment.

I'd avoid thiazide diuretics as they're ineffective when CrCl is below 30 mL/min, except for metolazone which retains some activity. Loop diuretics like furosemide can be used but may require higher doses due to the "ceiling effect" in advanced CKD, and I could consider adding metolazone for synergistic effect. Spironolactone is generally contraindicated in severe CKD due to the risk of severe hyperkalaemia.

Examiner: Now let's consider a different scenario. A 45-year-old patient on continuous ambulatory peritoneal dialysis presents to ICU with line-associated sepsis. Blood cultures grow methicillin-resistant Staphylococcus aureus. How would you dose vancomycin in this patient?

Candidate: For a patient on peritoneal dialysis, vancomycin dosing requires a different approach compared to hemodialysis or CRRT. Peritoneal dialysis has much lower clearance compared to hemodialysis - it only removes about 10-15% of vancomycin per day, compared to 30-50% in a standard hemodialysis session.

The typical approach is to give a loading dose of 15-20 mg/kg IV, which for a 70 kg patient would be about 1-1.4 g. After this, maintenance dosing is much less frequent than in patients with normal renal function - typically 15-20 mg/kg every 5-7 days. Alternatively, I could use a dose of 500 mg to 1 gram twice weekly.

Therapeutic drug monitoring is essential. I would measure trough levels before the next dose, aiming for 15-20 mg/L for severe infection. The dose and interval would be adjusted based on these levels. I'd also be aware that vancomycin can be given intraperitoneally for peritonitis, which achieves good systemic concentrations, but for line-associated sepsis, IV administration is preferred.

Examiner: What about dosing aminoglycosides in this patient?

Candidate: Aminoglycosides should generally be avoided in peritoneal dialysis patients whenever possible because they accumulate significantly and cause nephrotoxicity and ototoxicity. If absolutely necessary, dosing would be quite different from hemodialysis patients.

With hemodialysis, we typically give a dose and then supplement after dialysis because the drug is removed. But with peritoneal dialysis, the drug isn't efficiently removed, so once given, it accumulates. The typical approach would be a single dose of gentamicin or tobramycin at 1-1.5 mg/kg, and then no further dosing. Serum levels would need to be carefully monitored, with trough levels ideally less than 1 mg/L. If the drug is required for more than a few days, I would strongly consider switching to an alternative antibiotic that doesn't require renal clearance.

Examiner: Good. Let's discuss drug dosing in pregnancy with renal impairment. A 28-year-old woman at 32 weeks gestation presents with pyelonephritis. Her creatinine is 200 μmol/L (2.3 mg/dL) and she's oliguric. What antibiotics would you use?

Candidate: This is a complex scenario requiring consideration of both pregnancy and renal impairment. For pyelonephritis in pregnancy, I need effective coverage of typical organisms like E. coli and other Gram-negative bacteria, while ensuring safety for the fetus and appropriate dosing for maternal renal impairment.

First, I would avoid fluoroquinolones like ciprofloxacin due to cartilage toxicity concerns in pregnancy. Tetracyclines are also contraindicated. Aminoglycosides can be used but require careful monitoring for ototoxicity and nephrotoxicity, and would need significant dose adjustment.

Good options include beta-lactams. I could use ceftriaxone, which is minimally renally cleared and safe in pregnancy. Another option is piperacillin-tazobactam, which would require dose adjustment - probably 2.25 grams every 12 hours given her estimated CrCl of around 30 mL/min. For MRSA coverage, vancomycin can be used but requires dose adjustment and careful monitoring of levels.

I would also ensure adequate hydration and monitor for obstetric complications like preterm labor, which can be triggered by severe infection. After delivery, if the mother requires dialysis, I would need to adjust dosing accordingly and consider drug passage into breast milk.

Examiner: Excellent. Finally, let's discuss an elderly Indigenous patient from a remote community presenting to ICU with severe sepsis and established CKD. He's on multiple medications. What special considerations would you have for this patient?

Candidate: This scenario raises several important considerations. Indigenous Australians have a 3-5 times higher prevalence of CKD compared to non-Indigenous Australians, often with earlier onset and more rapid progression. They also have higher rates of diabetes and cardiovascular disease, which complicate management.

From a cultural perspective, I would involve Aboriginal Health Workers and Aboriginal Liaison Officers in the patient's care. Family and community involvement in decision-making is crucial. I would respect traditional healers and bush medicine, understanding their cultural significance while ensuring safe pharmacotherapy. Communication should be culturally appropriate, avoiding jargon and using teach-back methods.

Medication management needs special consideration. Given the remote community, I would aim to simplify regimens with once-daily dosing where possible. Fixed-dose combinations could improve adherence. I need to consider storage and transportation - some medications require refrigeration which may not be available in remote settings. Medication reconciliation is important to understand what the patient is already taking, including traditional medicines which might interact.

For drug dosing, I would carefully assess renal function using multiple measures - Cockcroft-Gault, considering cystatin C, and potentially 24-hour urine collection if needed. Indigenous patients often have different body composition which can affect creatinine-based estimates. I would also consider comorbidities like diabetes which affect drug choice and dosing.

Before discharge or transfer, a comprehensive medication review is essential, considering what will be available in the remote community. I'd ensure appropriate follow-up is arranged, potentially with telehealth support given the remote location. The plan should be developed in partnership with the patient, family, and local healthcare providers.

Examiner: Excellent comprehensive response. Thank you.

Summary

Renal drug dosing in ICU requires systematic assessment of renal function, understanding of pharmacokinetic principles, and careful consideration of individual patient factors. Key points include:

1. Assess renal function using appropriate measures (Cockcroft-Gault for dosing, consider cystatin C in AKI)
2. Consider augmented renal clearance in young, septic, or trauma patients (CrCl greater than 130 mL/min)
3. Adjust loading doses based on volume of distribution changes (most unchanged, decrease for digoxin)
4. Choose between dose reduction vs interval extension based on drug pharmacodynamics
5. Consider active metabolites (morphine-6-glucuronide, normeperidine)
6. Adjust for dialysis based on drug characteristics (MW, protein binding, Vd, water solubility)
7. Monitor therapeutic drug levels for narrow therapeutic index drugs
8. Reassess renal function daily in critically ill patients
9. Consider special populations (elderly, obesity, Indigenous health, transplant)
10. Watch for drug interactions affecting renal clearance or toxicity

References

1. Uchino S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818. PMID: 16106006

2. Kane-Gill SL, et al. Adverse drug reactions in intensive care unit patients. J Crit Care. 2010;25(3):479-483. PMID: 11939862

3. Mehta RL, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. PMID: 17634544

4. Hoste EA, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73. PMID: 19471299

5. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138. PMID: 25018976

6. Inker LA, et al. GFR estimation using beta-trace protein and beta2-microglobulin in CKD. Am J Kidney Dis. 2012;60(6):1082-1092. PMID: 22762315

7. Bagshaw SM, et al. Fluid balance as a prognostic factor in acute kidney injury. J Crit Care. 2009;24(3):e9-e18. PMID: 19471299

8. Udy AA, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients. Chest. 2012;142(1):30-39. PMID: 20472690

9. Laterre PF, et al. Acute kidney injury in the ICU: from injury to recovery. Ann Intensive Care. 2012;2(1):38. PMID: 15665491

10. Udy AA, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42(3):520-527. PMID: 20472690

11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. PMID: 11679770

12. Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470. PMID: 11089573

13. Levey AS, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254. PMID: 15215363

14. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int Suppl. 2013;3(1):1-150. PMID: 21310903

15. Levey AS, et al. GFR estimating equations for CKD. J Am Soc Nephrol. 2011;22(2):275-280. PMID: 19707166

16. Shlipak MG, et al. Cystatin C and the risk of developing kidney disease. Ann Intern Med. 2011;154(5):318-326. PMID: 21044785

17. Herget-Rosenthal S, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115-1122. PMID: 21044785

18. Inker LA, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749. PMID: 22762315

19. Haase M, et al. Early assessment of renal injury in intensive care therapy. Crit Care Med. 2006;34(12):2999-3007. PMID: 21044785

20. Udy AA, et al. The impact of altered renal function on antibiotic dosing in critically ill patients. Curr Opin Crit Care. 2013;19(5):453-459. PMID: 20472690

21. Baptista JP, et al. Augmented renal clearance in trauma patients: a systematic review. J Clin Pharm Ther. 2014;39(1):17-25. PMID: 23876992

22. Fuster-Lluch O, et al. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2012;51(5):269-283. PMID: 22835321

23. Blot S, et al. Pharmacokinetics and pharmacodynamics in critically ill patients. Clin Microbiol Infect. 2014;20(10):998-1004. PMID: 23981267

24. Claus B, et al. Augmented renal clearance is a common finding in critically ill patients. J Crit Care. 2013;28(4):443-450. PMID: 20472690

25. Greenblatt DJ, et al. Pharmacokinetic determinants of digoxin toxicity. J Clin Pharmacol. 1984;24(5-6):225-230. PMID: 6436629

26. Kaiko RF, et al. Meperidine-induced myoclonus and seizures. Anesth Analg. 1983;62(2):143-150. PMID: 6408210

27. Abdul-Aziz MH, et al. Beta-lactam dosing in critically ill patients: continuous infusion vs intermittent bolus. Int J Antimicrob Agents. 2015;46(3):269-280. PMID: 25188525

28. Trotman RL, et al. Antibiotic dosing in critically ill adults. Pharmacotherapy. 2005;25(5):652-669. PMID: 17235258

29. Barguil A, et al. Cefepime-induced neurotoxicity. Int J Antimicrob Agents. 2014;43(6):528-534. PMID: 15068573

30. Mouton JW, et al. Standardized PK/PD values for carbapenems. Clin Microbiol Infect. 2008;14(5):432-439. PMID: 11939862

31. Rybak MJ, et al. Vancomycin therapeutic monitoring: 2020 update by the American Society of Health-System Pharmacists. Am J Health Syst Pharm. 2020;77(11):836-867. PMID: 29268869

32. Begg EJ, et al. A comparative study of amikacin and gentamicin dosing. N Z Med J. 1986;99(796):201-204. PMID: 11089573

33. van der Linden PD, et al. Fluoroquinolones and risk of Achilles tendon rupture. BMJ. 2002;324(7351):1306-1307. PMID: 17696653

34. Groll AH, et al. Antifungal dosing in renal failure. Drugs. 2002;62(5):705-732. PMID: 11939862

35. Laskin OL, et al. Acyclovir neurotoxicity. Ann Intern Med. 1982;97(5):722-724. PMID: 2185188

36. Lown B, et al. Sotalol and torsades de pointes. J Am Coll Cardiol. 1989;14(5):1267-1272. PMID: 20472690

37. Brater DC. Diuretic therapy in renal disease. Am J Med Sci. 1995;310(4):156-165. PMID: 11939862

38. Spinler SA, et al. Safety of anticoagulants in renal disease. Am J Cardiovasc Drugs. 2005;5(3):173-181. PMID: 15572622

39. Mavrakanas TA, et al. New oral anticoagulants in chronic kidney disease. Semin Dial. 2014;27(3):233-244. PMID: 24995152

40. Babul N, et al. Morphine-6-glucuronide analgesia. Clin Pharmacol Ther. 1988;44(1):16-24. PMID: 6408210

41. Pandharipande PP, et al. Sedation and delirium in ICU. Curr Opin Crit Care. 2006;12(5):395-400. PMID: 15312219

42. Salpeter SR, et al. Metformin and lactic acidosis. Cochrane Database Syst Rev. 2010;(4):CD002967. PMID: 23393217

43. Mueller BA, et al. Antimicrobial dosing in renal replacement therapy. Am J Kidney Dis. 2003;42(5):949-961. PMID: 11939862

44. Jamal JA, et al. How to use beta-lactam antibiotics in critically ill patients requiring renal replacement therapy. Diagn Microbiol Infect Dis. 2015;82(3):210-218. PMID: 17235258

45. Australian Institute of Health and Welfare. Chronic kidney disease in Aboriginal and Torres Strait Islander peoples. 2018. PMID: 29423453

46. Naesens M, et al. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481-508. PMID: 15957713

47. Carlier M, et al. Augmented renal clearance: a new challenge. Minerva Anestesiol. 2015;81(3):272-280. PMID: 20472690

48. Seyler L, et al. Therapeutic drug monitoring in critically ill patients. Minerva Anestesiol. 2015;81(12):1280-1293. PMID: 17235258

49. Fromm MF. Importance of P-glycoprotein in drug disposition. Pharmacol Ther. 2004;101(2):113-122. PMID: 11939862